Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the Division of Select Agents and Toxins (DSAT) of the Centers for Disease Control and Prevention (CDC). The purpose of this MOU is to establish a procedure to allow CDC/DSAT to confirm that FDA has accepted or approved, under the authority of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq), an Investigational New Drug application (IND), a request to establish an Investigational New Animal Drug file (INAD), or an Investigational Device Exemption application (IDE) for a clinical trial involving the use of an investigational product that is, bears, or contains a select agent or toxin.
The agreement became effective January 25, 2008.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Jarilyn Dupont, Director of Regulatory Policy, Office of Policy and Planning (HF-11), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5906.End Further Info End Preamble Start Supplemental Information
In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the Federal Register, the agency is publishing notice of this MOU.Start Signature
Dated: February 8, 2008.
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S
[FR Doc. 08-686 Filed 2-15-08; 8:45 am]
BILLING CODE 4160-01-C